RTI-7470-44
Based on 1 Customer Validation
RTI-7470-44 is an orally active and blood-brain barrier-permeable antagonist of trace amine-associated receptor 1 (hTAAR1) with a Ki of 0.3 nM. RTI-7470-44 inhibits hTAAR1-mediated cAMP production and signal transduction (IC50 = 8.4 nM), and blocks hTAAR1-mediated GIRK current responses. RTI-7470-44 increases the spontaneous firing frequency of dopaminergic neurons and reduces collagen-induced platelet aggregation. RTI-7470-44 can be used in studies related to Parkinson's disease and gastric emptying.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 825658-63-7
- Formula: C19H11ClF3N5OS
- Molecular Weight:449.84
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
|
TAAR1 8.4 nM (IC50) |
RTI-7470-44 potently and competitively inhibits hTAAR1-mediated cAMP production in hTAAR1-CHO cells, with an IC50 value of 8.4 nM[1].
RTI-7470-44 inhibits rTAAR1-mediated cAMP production in rTAAR1-HEK293 cells with an IC50 of 748 nM (as a potential non-competitive antagonist), and suppresses mTAAR1-mediated cAMP production in mTAAR1-HEK293 cells with an IC50 of 1190 nM[1].
RTI-7470-44 binds competitively to hTAAR1 membranes with a Ki value of 0.3 nM; it binds to mTAAR1 membranes with a Ki value of 139 nM, but enhances the binding of radioligands to rTAAR1 membranes[1].
RTI-7470-44 exhibits moderate affinity for rat BZP brain sites (Ki = 1 μM), extremely weak affinity for human sigma 2 receptors (Ki = 8.4 μM), and very low off-target activity against a panel of 42 other targets at a concentration of 10 μM[1].
RTI-7470-44 potently inhibits human TAAR1 with an EC50 of 167.6 nM[2].
RTI-7470-44 (40 nM) blocks TAAR1-mediated reduction of lipid accumulation, steatosis and phospholipidosis in differentiating 3T3-L1 adipocytes[2].
RTI-7470-44 (1 µM) weakly reverses Ralmitaront (HY-109157)-induced activation of GIRK channels in Xenopus oocytes expressing human TAAR1, reducing the response by 20%[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 22-27 g)[2]
-
Dosage:5 mg/kg (co-administered with JP-14 10 mg/kg); 5 mg/kg (single agent)
-
Administration:i.g.; single dose
-
Result:Reduced JP-14's inhibition of gastric emptying from ~66% to ~25%.
Did not affect gastric emptying when administered alone, with phenol red levels in the stomach comparable to vehicle controls.
Chemical Information
-
CAS No. 825658-63-7
-
Appearance Solid
-
Molecular Weight 449.84
-
Formula C19H11ClF3N5OS
-
Color Off-white to light yellow
-
SMILES
N#CC1=C(SCC(NC2=NC=CC=N2)=O)N=C(C3=CC=C(Cl)C=C3)C=C1C(F)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 20.83 mg/mL (46.31 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1].
Decker AM, et al. Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist. ACS Chem Neurosci. 2022 Apr 6;13(7):1082-1095.
[Content Brief]
[2].
Marcinkowska M, et al. JP-14: A Trace Amine-Associated Receptor 1 Agonist with Anti-Metabolic Disorder Potential. Int J Mol Sci. 2025 Oct 15;26(20):10033.
[Content Brief]
[3].
Ågren R, et al. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics. Int J Neuropsychopharmacol. 2023 Sep 25;26(9):599-606.
[Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2230 mL | 11.1151 mL | 22.2301 mL | 55.5753 mL |
| 5 mM | 0.4446 mL | 2.2230 mL | 4.4460 mL | 11.1151 mL | |
| 10 mM | 0.2223 mL | 1.1115 mL | 2.2230 mL | 5.5575 mL | |
| 15 mM | 0.1482 mL | 0.7410 mL | 1.4820 mL | 3.7050 mL | |
| 20 mM | 0.1112 mL | 0.5558 mL | 1.1115 mL | 2.7788 mL | |
| 25 mM | 0.0889 mL | 0.4446 mL | 0.8892 mL | 2.2230 mL | |
| 30 mM | 0.0741 mL | 0.3705 mL | 0.7410 mL | 1.8525 mL | |
| 40 mM | 0.0556 mL | 0.2779 mL | 0.5558 mL | 1.3894 mL |